Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment

Author Tur, Carmen Google Scholar
Tintore, Mar Google Scholar
Vidal-Jordana, Angela Google Scholar
Bichuetti, Denis Autor UNIFESP Google Scholar
Nieto Gonzalez, Pablo Google Scholar
Jesus Arevalo, Maria Google Scholar
Arrambide, Georgina Google Scholar
Anglada, Elisenda Google Scholar
Galan, Ingrid Google Scholar
Castillo, Joaquin Google Scholar
Jordi Rio, Carlos Nos Google Scholar
Isabel Martin, Maria Google Scholar
Comabella, Manuel Google Scholar
Sastre-Garriga, Jaume Google Scholar
Montalban, Xavier Google Scholar
Institution Vall dHebron Univ Hosp
Universidade Federal de São Paulo (UNIFESP)
Univ Hosp Principe de Asturias
Abstract Objective: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance.Methods: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits' scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.Results: No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). in low PML-risk subgroups (C-E), higher RAS were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS in either group.Conclusions: Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits.
Language English
Sponsor Bayer Health Care
Merck Serono
Date 2013-12-10
Published in Plos One. San Francisco: Public Library Science, v. 8, n. 12, 7 p., 2013.
ISSN 1932-6203 (Sherpa/Romeo, impact factor)
Publisher Public Library Science
Extent 7
Origin http://dx.doi.org/10.1371/journal.pone.0082796
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000328707400096
URI http://repositorio.unifesp.br/handle/11600/37076

Show full item record


Name: WOS000328707400096.pdf
Size: 257.8Kb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account